Non-diabetic chronic kidney disease research hub

(21177) A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease

This study is looking into a new medication called Finerenone for people with long-term kidney disease that isn't caused by diabetes. It aims to see if the drug can slow down kidney disease progression and if it's safe to use, compared to a dummy pill.